Group leader:
Prof. Reijo Laaksonen

Group pages:
Not available

Latest publications:

2020

Mishra BH, Mishra PP, Mononen N, Hilvo M, Sievänen H, Juonala M, Laaksonen M, Hutri-Kähönen N, Viikari J, Kähönen M, Raitakari OT, Laaksonen R, Lehtimäki T
Lipidomic architecture shared by subclinical markers of osteoporosis and atherosclerosis: The Cardiovascular Risk in Young Finns Study.
Bone ;2020
PMID

Busnelli M, Manzini S, Bonacina F, Soldati S, Barbieri SS, Amadio P, Sandrini L, Arnaboldi F, Donetti E, Laaksonen R, Paltrinieri S, Scanziani E, Chiesa G
Fenretinide treatment accelerates atherosclerosis development in apoE-deficient mice in spite of beneficial metabolic effects.
Br J Pharmacol ;177(2)328-345, 2020
PMID

Hilvo M, Meikle PJ, Pedersen ER, Tell GS, Dhar I, Brenner H, Schöttker B, Lääperi M, Kauhanen D, Koistinen KM, Jylhä A, Huynh K, Mellett NA, Tonkin AM, Sullivan DR, Simes J, Nestel P, Koenig W, Rothenbacher D, Nygård O, Laaksonen R
Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.
Eur Heart J ;41(3)371-380, 2020
PMID

2019

Kiamehr M, Alexanova A, Viiri LE, Heiskanen L, Vihervaara T, Kauhanen D, Ekroos K, Laaksonen R, Käkelä R, Aalto-Setälä K
hiPSC-derived hepatocytes closely mimic the lipid profile of primary hepatocytes: A future personalised cell model for studying the lipid metabolism of the liver.
J Cell Physiol ;234(4)3744-3761, 2019
PMID

Silbernagel G, Scharnagl H, Kleber ME, Delgado G, Stojakovic T, Laaksonen R, Erdmann J, Rankinen T, Bouchard C, Landmesser U, Schunkert H, März W, Grammer TB
LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study.
Atherosclerosis ;2019
PMID